HRMY - NASDAQ
Harmony Biosciences Holdings, Inc.
$32.10
+0.91%Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
At a Glance
Live SnapshotHarmony Biosciences Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Harmony Biosciences Holdings, Inc. Cash Flow Statement
HRMY • NASDAQ
| Harmony Biosciences Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
158.7M | 145.5M | 128.9M | 181.5M | 34.6M | -36.9M | -152M | -39.9M | |
25.3M | 24.1M | 24.4M | 25M | 21.1M | 10.2M | 3.8M | 184K | |
0.0 | -29.3M | -13.4M | 0.0 | 0.0 | 25.7M | 0.0 | 0.0 | |
44.9M | 42.6M | 31.7M | 26.9M | 16.1M | 4.7M | 9.9M | 1.1M | |
27.5M | 44.2M | 12.9M | -82.1M | 24.6M | 4.9M | 59.4M | 2.1M | |
(0.0) | (79.6M) | (48.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
91.8M | -7.3M | 35M | -6.9M | 2.2M | -11.6M | 3.4M | -164K | |
348.2M | 219.8M | 219.4M | 144.5M | 98.6M | -3M | -75.4M | -38.8M | |
INVESTING ACTIVITIES | ||||||||
-19.6M | -1.2M | -312K | -172K | -298K | -2M | -149K | -1.3M | |
(0.0) | -33.1M | -37M | (0.0) | (0.0) | -2M | (0.0) | (0.0) | |
-86.2M | -105.3M | -127.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
81.1M | 98.5M | 118.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-15M | -26.5M | 0.0 | -141.7M | -100M | 2M | -127M | 0.0 | |
-39.6M | -67.5M | -46.4M | -141.8M | -100.3M | -2M | -127.1M | -1.3M | |
FINANCING ACTIVITIES | ||||||||
10.2M | 6.5M | -100M | 0.0 | 0.0 | 147.5M | 0.0 | -3.2M | |
-16.3M | -15M | -1.3M | -2M | -500K | 79.4M | 100M | 0.0 | |
(0.0) | (0.0) | -100M | (0.0) | (0.0) | -167K | (0.0) | -3.2M | |
-3M | -2.5M | -3.8M | 8.8M | 7.9M | 129.9M | 43.8M | -185K | |
-9M | -11M | -105.6M | 6.8M | 7.4M | 209.2M | 143.8M | 21.6M | |
CASH FLOW SUMMARY | ||||||||
299.5M | 141.3M | 67.4M | 9.5M | 5.7M | 204.2M | -58.8M | -18.5M | |
453M | 311.9M | 244.5M | 235.1M | 229.4M | 25.2M | 84M | 102.5M | |
752.5M | 453.3M | 311.9M | 244.5M | 235.1M | 229.4M | 25.2M | 84M | |
347.9M | 218.7M | 219.1M | 144.3M | 98.3M | -5M | -75.6M | -40.1M |
SEC Filings
HRMY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Related Guides
Continue your HRMY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.